FSD Pharma Inc. Form 20-F Summary
Filing identity: The provided filing is for FSD Pharma Inc., not Quantum Biopharma Ltd. It is an annual Form 20-F for the fiscal year ended December 31, 2023, filed April 1, 2024. The filing presents audited consolidated financial statements under IFRS in U.S. dollars. It does not provide a standalone 2023 fourth-quarter report.
Business Context and Reporting Period
FSD is an early-stage biopharmaceutical company focused primarily on Lucid-MS, a multiple sclerosis drug candidate, and treatments for alcohol misuse. It also operates a strategic-investments business consisting primarily of loans secured by residential property. The company has no approved pharmaceutical products and has not generated revenue from pharmaceutical product sales.
- Lucid-MS completed first-in-human Phase 1 dosing in 2023. Management reported that the Phase 1 study was safe and well tolerated at single doses of 50–300 mg, subject to the limitations of preliminary clinical development.
- FSD licensed recreational alcohol-misuse applications and related trademarks to Celly Nutrition Corp. in July 2023. FSD retained medical and pharmaceutical applications.
- FSD paused Lucid-PSYCH development and discontinued FSD-PEA development in 2023 to prioritize cash and resources.
- As of December 31, 2023, FSD employed eight full-time employees and one part-time employee.
Financial Performance and Position
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue from pharmaceutical or other product sales | None reported | None reported |
| Interest income | $0.8 million | $0.4 million |
| Operating expenses | $23.8 million | $27.4 million |
| Net loss from continuing operations | $18.2 million | $26.7 million |
| Net loss | $18.2 million | $23.6 million |
| Basic and diluted loss per share | $0.46 | $0.69 |
| Cash used in operating activities | $10.8 million | $28.3 million |
| Cash and cash equivalents at year-end | $2.8 million | $17.0 million |
| Total assets | $17.5 million | $38.4 million |
| Total liabilities | $4.6 million | $7.9 million |
| Shareholders’ equity, including non-controlling interests | $12.9 million | $30.5 million |
The filing does not provide a meaningful revenue-based gross margin or operating margin because the company reported no product-sales revenue. On reported figures, operating expenses declined approximately 13% year over year, while the net loss from continuing operations declined approximately 32%.
- General and administrative expense was $9.0 million, compared with $14.5 million in 2022.
- External research and development expense was $3.9 million, compared with $6.9 million in 2022.
- Share-based compensation increased to $3.8 million from $1.5 million.
- The company recognized a $4.6 million impairment loss, including impairments related to discontinued or deprioritized intellectual property.
- A $4.9 million gain from remeasurement of a financial liability materially reduced the reported net loss.
- Finance receivables totaled $8.1 million, principally secured by residential property; $7.2 million was classified as current.
- Current liabilities were $4.6 million, including $4.2 million of trade and other payables. The company reported no long-term debt; notes payable of approximately $0.3 million were due on demand.
- Working capital was approximately $6.5 million, but cash alone was $2.8 million at year-end.
Cash Flow, Liquidity and Going Concern
Cash declined by $14.2 million during 2023, from $17.0 million to $2.8 million. Operating cash burn was $10.8 million, investing activities used $0.3 million and financing activities used $3.1 million, principally due to share repurchases.
The auditor included a material uncertainty related to going concern. Management disclosed an accumulated deficit of $157.9 million, continuing losses, negative operating cash flow and the need to raise additional capital. The financial statements do not include adjustments that might result if the company cannot continue as a going concern.
Material Changes Versus the Prior Comparable Period
- FSD’s net loss from continuing operations improved from $26.7 million to $18.2 million, but the company remained unprofitable and cash reserves fell substantially.
- Operating expenses decreased, primarily because of lower general and administrative, research and development, and amortization expenses.
- FSD recorded a $4.6 million impairment charge and a $4.9 million non-cash gain from liability remeasurement, making reported earnings less indicative of recurring operating performance.
- FSD acquired control of Celly in July 2023 for accounting purposes and consolidated Celly’s results from July 31 through year-end, despite holding 26.15% of Celly at December 31, 2023. Management cited de facto control through combined voting rights and board representation.
- FSD distributed 45.7 million Celly shares to its securityholders in November 2023 and retained 154.3 million Celly shares, representing approximately 26.15% of Celly on a non-diluted basis.
- FSD repurchased 1.9 million Class B shares for approximately C$4.0 million at an average price of approximately C$2.11 per share.
- FSD issued 3.975 million warrants for consulting services and ended the year with 10.3 million warrants outstanding, in addition to 2.5 million share options outstanding under its equity incentive plan.
Guidance, Outlook, Risks and Unusual Items
- Management plans to advance Lucid-MS toward Phase 2, subject to additional multiple-ascending-dose data, toxicology results, regulatory requirements and financing.
- Management estimates approximately US$30.7 million to advance the Lucid-MS program toward commercialization and approximately US$11.0 million for the healthcare alcohol-misuse program. These are forward-looking estimates and are contingent on financing and regulatory approvals.
- In February 2024, FSD established an ATM facility permitting sales of up to approximately US$11.2 million of Class B shares. Any use of the facility could dilute existing holders.
- Key risks include the absence of product revenue, uncertain clinical efficacy and safety, regulatory approval risk, dependence on third-party research and manufacturing providers, intellectual-property challenges, limited cash, potential dilution, and the need for additional financing.
- The company believes it was a passive foreign investment company for U.S. federal income tax purposes in 2023 and expects it may remain a PFIC, potentially creating adverse tax consequences for U.S. holders.
- FSD disclosed ongoing litigation, including a GBB Drink Lab lawsuit alleging trade-secret misappropriation and breach of a nondisclosure agreement, with claimed damages of approximately US$53.0 million. The company disputes the allegations.
- FSD settled a CRO dispute for US$100,000, compared with a prior arbitration award of approximately US$1.7 million plus interest, resulting in a material liability remeasurement gain.
- A related-party mortgage loan of C$1.2 million was made to the CEO. It is secured by a second-charge mortgage, and the company acknowledged uncertainty regarding compliance with the applicable U.S. executive-loan exemption.
- The dual-class structure gives Class A shares 276,660 votes per share versus one vote per Class B share. The Class A holders collectively controlled approximately 33.6% of voting power as of March 28, 2024.
Most Important Facts to Verify
- Confirm the requested issuer: the supplied filing is FSD Pharma Inc., while the request identifies Quantum Biopharma Ltd.
- Review the complete 2023 Annual MD&A referenced as Exhibit 15.1 for detailed quarterly trends, liquidity analysis and management’s financing assumptions.
- Assess the going-concern disclosure, current cash of $2.8 million and expected cash requirements for Lucid-MS and alcohol-misuse programs.
- Verify whether the company raised capital under the US$11.2 million ATM facility after the filing date and quantify resulting dilution.
- Evaluate the clinical evidence supporting advancement of Lucid-MS to Phase 2, including final data, safety findings, toxicology requirements and regulatory status.
- Review the Celly consolidation judgment, the value and liquidity of retained Celly shares, the Celly loan and royalty economics.
- Quantify potential exposure from the GBB litigation and other continuing legal proceedings.
- Review outstanding warrants, options and other potentially dilutive securities, including their exercise prices and expiration dates.